急性痘疮样苔藓样糠疹1例

患者女,48岁。周身泛发性红色丘疹、丘疱疹伴瘙痒10余日,皮疹多为粟粒至黄豆大小,上覆少许薄鳞屑,Ausptiz征(-),部分皮损破溃、坏死、血痂。皮损组织病理示:表皮细胞间水肿及细胞内水肿形成多房性表皮内疱,疱内见中性粒细胞及多量红细胞,基底细胞液化,区域性淋巴样细胞浸润。诊断:急性痘疮样苔藓样糠疹。     

儿童苔藓样糠疹:对红霉素的治疗反应

苔藓样糠疹(PL)是一种不常见的皮肤病,分急性痘疮样苔藓样糠疹(PLVA, Mucha-Habermann病)与慢性苔藓样糠疹(PLC, Juliusberg型)两种病型。PLVA能出现出血性、小疱或脓疱甚至坏死性皮损,并可后遗疤痕和色素性改变,持     

急性痘疮样苔藓样糠疹1例及文献复习

患者男,47岁,躯干、四肢皮肤见泛发粟粒至黄豆大红色斑丘疹20天,丘疹上覆少许稀薄鳞屑,Auspit征(-),部分皮损中央破溃,坏死、结痂。患者无发热、淋巴结及肝脾肿大。组织病理示:表皮呈灶性变性坏死,区域性淋巴浸润。诊断:急性痘疮样苔藓样糠疹。本文并就其病因、临床表现、病理进展和治疗进行了文献复习。     

苔藓样糠疹

苔藓样糠疹(pityriasis lichenoides)有三种不同的类型,分别为发热溃疡坏死性苔藓样糠疹(pityriasis lichenoides with ulceronecrotic hyperthermia,PLUH)、急性苔藓痘疮样糠疹(pityriasis lichenoides et varioliformis acuta,PLEVA)、慢性苔藓样糠疹(pityriasis lichenoides chronica,PLC).在三型之间有一些移行状态,分别具有不同亚型的特点,说明这三种亚型之间是有联系的,一些患者可以同时有PLEVA和PLC的皮损表现.     

发热性溃疡坏死性急性痘疮样苔藓样糠疹1例

报告1例发热性溃疡坏死性急性痘疮样苔藓样糠疹。患者女,19岁。躯干红斑、水疱、坏死1个月,加重2周伴发热3天。右手臂丘疱疹处组织病理检查:表皮较多坏死角朊细胞,部分融合成片,炎细胞进入表皮,基底细胞液化变性;真皮血管周围及汗腺周围淋巴细胞浸润,部分血管壁纤维束样变性,红细胞外溢。诊断:发热性溃疡坏死性急性痘疮样苔藓样糠疹。予环孢素、人丙种球蛋白、甲氨蝶呤及糖皮质激素等多个阶段治疗后,病情好转。随访5个月无复发。     

急性痘疮样苔藓样糠疹64例临床分析

目的:分析急性痘疮样苔藓样糠疹(PLEVA)临床特征和疗效。方法:对64例PLEVA患者进行回顾性分析。结果:(1)64例患者中男女发病率之比为4.3∶1;(2)29.69%的患者发病前有感染史,93.75%的患者皮损具有多形性,43.75%症状较重者出现白细胞计数、转氨酶、免疫球蛋白(IgM、IgG、IgA)等实验室检查指标异常;(3)组织病理:淋巴细胞性血管炎,淋巴细胞、红细胞游人表皮为特征;(4)糖皮质激素、窄波中波紫外线(NB-UVB)、雷公藤多苷、四环素、甘草酸二胺等联合治疗有效。结论:PLEVA临床表现多样性,治疗以糖皮质激素为主。     

发热溃疡坏死性急性痘疮样苔藓样糠疹的护理

总结1例发热溃疡坏死性急性痘疮样苔藓样糠疹的护理要点,包括:严密监测病情,针对皮损的程度实施皮肤创面综合护理,做好留置导尿护理,营养支持,心理护理。     

淋巴瘤样丘疹病1例

患者男,48岁。因躯干和四肢反复出现红斑,丘疹、结节3年,于2004年6月28日至我院就诊。3年前患者无明显诱因,躯干、四肢出现散在孤立的红色丘疹、结节,皮损大小不等,中央有坏死结痂,愈后留有色素沉着和瘢痕。在当地医院诊断为急性痘疮性苔藓样糠疹,未予治疗,皮损数周后消退。     

急性痘疮样苔藓样糠疹1例

急性痘疮样苔藓样糠疹又称痘疮样型副银屑病,现将我院诊治的1例报道如下. 临床资料 患者男,34岁.半月前旅途疲劳之后,躯干出现散在的红色丘疹,粟粒至绿豆大,质硬.自觉瘙痒.到当地医院就诊,给予青霉素80万U静滴,2天后,皮损基本消退,部分皮损留有色素沉着.     

急性痘疮样苔藓状糠疹1例

急性痘疮样苔藓状糠疹又名急性痘疮样副银屑病，较为少见，我所遇1例报道如下。     

环氧化酶-2在表皮肿瘤中的表达

目的 探讨环氧化酶-2在不同表皮肿瘤中的表达及意义。方法 选择鳞状细胞癌8例、基底细胞上皮瘤10例、Bowen病8例和脂溢性角化病12例,运用免疫组化方法观察肿瘤细胞中环氧化酶-2的表达。结果 与正常表皮相比,环氧化酶-2在鳞状细胞癌、Bowen病、基底细胞上皮瘤中的表达明显上调,尤其以鳞状细胞癌中的表达最强。而环氧化酶-2在脂溢性角化病中的表达与正常人皮肤的表达近似。结论 环氧化酶-2表达的上调可能在表皮肿瘤的发生发展中发挥一定作用。     

Leprosy: a review of laboratory and therapeutic aspects - Part 2

Leprosy is a chronic infectious condition caused by Mycobacterium leprae(M. leprae). It is endemic in many regions of the world and a public health problem in Brazil. Additionally, it presents a wide spectrum of clinical manifestations, which are dependent on the interaction between M. leprae and host, and are related to the degree of immunity to the bacillus. The diagnosis of this disease is a clinical one. However, in some situations laboratory exams are necessary to confirm the diagnosis of leprosy or classify its clinical form. This article aims to update dermatologists on leprosy, through a review of complementary laboratory techniques that can be employed for the diagnosis of leprosy, including Mitsuda intradermal reaction, skin smear microscopy, histopathology, serology, immunohistochemistry, polymerase chain reaction, imaging tests, electromyography, and blood tests. It also aims to explain standard multidrug therapy regimens, the treatment of reactions and resistant cases, immunotherapy with bacillus Calmette-Guérin (BCG) vaccine and chemoprophylaxis.     

白塞综合征患者抗血管内皮细胞抗体和抗心磷脂抗体的检测

目的 探讨血清抗血管内皮细胞抗体(AECA)及抗心磷脂抗体(ACA)在白塞综合征发病中的作用。方法 收集白塞综合征患者和正常人血清,用间接免疫荧光技术检测血清中AECA并分型,用酶联免疫吸附方法检测ACA。结果 白塞综合征组AECA阳性率为81.3%(32例中26例阳性),其中IgG-AECA阳性率为71.9%,IgM-AECA阳性率为53.1%,与正常人对照组比较差异有显著性(P<0.01)。同时AECA阳性组与阴性组比较在发生结节性红斑或结节性血管炎及血沉增快方面前者高于后者。ACA检测结果,白塞综合征组阳性率为53.1%,显著高于正常人对照组。ACA阳性组与阴性组比较,在口腔溃疡、皮肤、外生殖器及贫血等临床表现及血沉等方面差异无显著性(P>0.05)。结论 白塞综合征患者血清AECA水平对白塞综合征血管损害及病情活动具有一定意义。ACA对病情的影响尚需进一步研究。     

缓和性血清阴性对称性滑膜炎伴凹陷性水肿综合征一例并文献复习

目的了解缓和性血清阴性对称性滑膜炎伴凹陷性水肿综合征的临床表现。方法分析1例缓和性血清阴性对称性滑膜炎伴凹陷性水肿综合征患者临床表现、实验室检查及治疗反应。结果患者男,54岁,表现为对称性多关节炎及肢端水肿。血清类风湿因子、抗核抗体、抗ds—DNA抗体、抗合成循环瓜氨酸多肽抗体、免疫球蛋白、补体均正常。x线检查示双手掌指骨骨质破坏。糖皮质激素和免疫抑制剂治疗效果好。结论缓和性血清阴性对称性滑膜炎伴凹陷性水肿综合征是一组异质性疾病。     

线状和回旋状色素沉着症并发炎性线状表皮痣及寻常性鱼鳞病

报告1例线状和回旋状色素沉着症并发炎性线状表皮痣、寻常性鱼鳞病。患者女,17岁。2岁起胸背部出现线状和回旋状色素沉着,双下肢皮损覆鱼鳞状鳞屑,双手背关节和左侧膝部、踝部、足背关节处可见线状鳞屑性红斑。系统及实验室检查均正常。结合组织病理改变诊断为线状和回旋状色素沉着症并发炎性线状表皮痣、寻常性鱼鳞病。     

Update summarising the conclusions of the international consultation on male lower urinary tract symptoms

The International Consultation on Urological Disease have recently published comprehensive conclusions, based on evidence reviewed by eight committees, on aspects of male lower urinary tract symptoms(LUTS). In this review, we summarise the conclusions from fourof the committees, namely, the evidence regarding the epidemiology of male LUTS, patient assessment, nocturia and medical management. It is indisputable that with an expanding and ageing global population the prevalence of male LUTS is likely to increase. Therefore symptom prevention and preservation of quality of life(Qo L) feature highly in the guidelines. There are now a number of different medical options, proven to lead to significant improvements in symptom scores, flow rate and Qo L available to men with LUTS. Metaanalyses have shown the benefits for alpha blockers, antimuscarinics, 5-α reductase and phosphodiesterase-5 inhibitors. High level evidence also exists for combinations of all of the above with alpha blockers and so men with concomitant storage symptoms, prostate volume 30 mL, PSA 1.4 or erectile dysfunction may be considered for combination treatment of an alpha blocker with an antimuscarinic, 5-α reductase inhibitor or phosphodiesterase-5 inhibitor respectively. In an era of personalised medicine, appropriate patient selection is likely to provide the key to the most effective clinical management strategy.     

Sweet side of bladder cancer

The malignant transformation of cells is often accompanied by deranged expression of the sugar chains,i.e.,glycans,attached the cancer cell surfaces or attached to secreted proteins.The aberrant expression of specific glycans in bladder cancer has also been reported by several research groups.Similarly to other cancers,glycans such as the sialyl Tn antigens have been suggested as diagnostic and prognostic biomarkers of bladder cancer,and associated with disease progression and patient’s response to treatment.At present our understandings about the role of glycans in bladder cancer is still limited,but at the same time it is now assumed that this understanding urges and it will fuel the development of novel strategies of diagnostic and therapy.